Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Patients | Phase | Treatment | n | OS (m) | PFS (m) | TTP (m) | RR | DCR |
Pretreated patients with advanced gastric cancer | II | Sunitinib | 51 | 5.8 | 1.28 | N/A | 3.9% | 20.0% |
Second line treatment for advanced gastric cancer | II | Sunitinib | 78 | 6.8 | 2.3 | 2.3 | 2.6% | 34.7% |
Unresectable or metastatic advanced gastric cancer after failed treatment with fluoropyrimidine + platinum | II | Docetaxel | 49 | 6.6 | N/A | 2.6 | 14.3% | 51.0% |
Docetaxel + sunitinib | 56 | 8.0 | N/A | 3.9 | 41.1% | 75.0% |
- Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741